ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Up 19.1% in January

ProPhase Labs, Inc. (NASDAQ:PRPH) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 116,400 shares, an increase of 19.1% from the December 31st total of 97,700 shares. Based on an average daily trading volume, of 290,200 shares, the short-interest ratio is currently 0.4 days.

ProPhase Labs Price Performance

NASDAQ:PRPH traded up $0.00 during trading hours on Monday, hitting $0.27. 15,034,780 shares of the company’s stock traded hands, compared to its average volume of 1,119,311. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $0.64 and its two-hundred day simple moving average is $1.71. ProPhase Labs has a 52 week low of $0.22 and a 52 week high of $7.48. The firm has a market cap of $6.37 million, a P/E ratio of -0.21 and a beta of -0.36.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on ProPhase Labs in a report on Saturday. They set a “sell” rating for the company.

Hedge Funds Weigh In On ProPhase Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in PRPH. Sheets Smith Wealth Management purchased a new position in ProPhase Labs during the fourth quarter valued at $158,000. HighTower Advisors LLC raised its holdings in shares of ProPhase Labs by 18.3% in the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after purchasing an additional 27,673 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of ProPhase Labs by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after buying an additional 13,590 shares in the last quarter. Institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.